ALGN · XBRL financial data

Align Technology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2,472	3,953	3,735	3,862	3,999	4,035
Cost of revenue	709	1,017	1,101	1,155	1,200	1,324
Gross profit	1,763	2,935	2,634	2,707	2,799	2,711
Research and development	175	250	305	347	364	370
Selling, general and administrative	1,201	1,709	1,674	1,703	1,763	1,756
Total operating expenses	1,376	1,959	1,991	2,064	2,192	2,165
Operating income (loss)	387	976	643	643	608	546
Income tax expense (benefit)	(1,397)	240	237	196	188	175
Net income (loss)	1,776	772	362	445	421	410
Earnings per share, basic USD per share	22.55	9.78	4.62	5.82	5.63	5.66
Earnings per share, diluted USD per share	22.41	9.69	4.61	5.81	5.62	5.65
Weighted average shares, basic millions of shares	79	79	78	76	75	73
Weighted average shares, diluted millions of shares	79	80	78	77	75	73

Fiscal years (ALGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	961	1,099	942	937	1,044	1,095
Marketable securities	0	72	58	35	0	—
Marketable securities, non-current	0	125	42	8	0	—
Accounts receivable	658	897	860	903	996	1,102
Inventory	139	230	339	297	254	226
Prepaid and other current assets	92	195	226	274	199	166
Total current assets	1,850	2,494	2,424	2,447	2,492	2,617
Property and equipment, net	735	1,082	1,232	1,291	1,271	1,131
Right-of-use asset	83	121	119	118	113	108
Goodwill	445	419	408	420	443	492
Total assets	4,830	5,942	5,948	6,084	6,215	6,234
Accounts payable	142	164	128	113	109	121
Accrued liabilities	406	607	454	526	598	537
Total current liabilities	1,326	1,924	1,926	2,067	2,038	1,920
Lease liability, non-current	64	103	100	97	88	83
Total liabilities	1,596	2,319	2,347	2,453	2,363	2,185
Retained earnings	2,216	2,619	2,567	2,447	2,484	2,464
Total stockholders' equity	3,234	3,623	3,601	3,630	3,852	4,049
Total liabilities and equity	4,830	5,942	5,948	6,084	6,215	6,234
Common shares outstanding (cover page) millions of shares	79	79	77	75	74	71

Fiscal years (ALGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	1,776	772	362	445	421	410
Stock-based compensation	98	114	133	154	174	186
Depreciation and amortization	94	109	126	142	145	237
Net cash from operating activities	662	1,173	569	786	738	593
Purchases of property and equipment	155	401	292	178	116	102
Net cash from investing activities	(232)	(563)	(213)	(196)	(255)	(112)
Proceeds from issuing common stock	20	26	26	27	25	22
Share repurchases	0	375	435	592	353	466
Net cash from financing activities	(31)	(458)	(502)	(598)	(356)	(465)
Net change in cash	410	139	(158)	(4)	106	51

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Align Technology	1,145	1,015	183*	70.5M	—	Q3 FY26 10-QSep 30, 2026
Penumbra	254	410	42*	39.4M	—	Q3 FY26 10-QSep 30, 2026
Medline	2,327	7,685	715*	not reported	—	Q2 FY26 10-QJun 27, 2026
Solventum	403	2,209	227*	170.2M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Hologic	2,168	1,048	230	223.2M	—	Q1 FY26 10-QDec 27, 2025
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
Zimmer Biomet Holdings	400	2,063	not reported	189.3M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.